Finasteride therapy in a dog with benign prostatic hyperplasia

• Published in: Journal of animal reproduction & biotechnology (Online) Vol. 37; no. 3; pp. 209 - 212
• Main Author: Kim, Hyejin
• Format: Journal Article
• Language: English
• Published: The Korean Society of Animal Reproduction and Biotechnology 30.09.2022; 사단법인 한국동물생명공학회
• Subjects: 5-α reductase inhibitor; benign prostatic hyperplasia; dog; finasteride; treatment; 축산학
• ISSN: 2671-4639; 2671-4663
• DOI: 10.12750/JARB.37.3.209

Benign prostatic hyperplasia (BPH) is frequently observed in intact middle-aged or older male dogs with symptoms ranging from asymptomatic to various symptoms such as urination, dyschezia, dysuria, tenesmus, and intermittent serosanguinous or clear serous exudate. A 4-year-old, intact male Welsh corgi with symptoms of intermittent hematuria and serosanguinous exudate at the urethral opening was diagnosed with BPH and intraprostatic hematocyst through ultrasonographic examination and cytology test. The dog was internationally adopted for reproductive purposes and needed to undergo BPH treatment while maintaining fertility. Thus, 2.5 mg finasteride was administered orally once a day for treatment option and therapeutic effects were observed, including loss of clinical symptoms and reduced prostate and intraparenchymal cyst size.